GNRH1 and ovarian hyperstimulation syndrome: However, this therapy has proven to have some limits because of the increased incidence of ovarian hyperstimulation syndrome (OHSS) by GnRH agonists and the rate of premature LH surges (0.34–38.3%) via GnRH antagonists3,4.